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ABSTRACT
Introduction: Pemphigus vulgaris (PV) is a
chronic, autoimmune, vesiculobullous disease.
As a result of the relative rarity of PV, published
randomized controlled trials (RCTs) are limited,
which makes it difficult to evaluate the efficacy
of different treatment regimens in this disease.
This also precludes conduct of a meta-analysis.
Methods: English-language publications
describing treatment outcomes of patients
with PV were identified by searches of
electronic databases through May 2015, and
additionally by review of the bibliography of
these publications. A total of 89 papers, which
included 21 case reports, 47 case series, 8 RCTs,
and 13 observational studies, were identified.
The findings from these publications, including
information on disease course and prognosis,
medications used, treatment responses, and side
effects, are summarized in the tables and text of
this review.
Results: Prior to availability of corticosteroid
therapy, PV had a high fatality rate. Early
publications from the 1970s reported
high-dose, prolonged corticosteroid use and
significant associated side effects. Later reports
described use of corticosteroids along with
steroid-sparing adjuvants, which allows a
reduction in the total dose of corticosteroids
and a reduction in observed mortality and
morbidity. For the majority of patients in
these reports, a long-term course on
medications lasting about 5–10 years was
observed; however, subgroups of patients
requiring shorter courses or needing
longer-term therapy have also been described.
Early diagnosis of PV and early initiation of
treatment were prognostic factors. In recent
publications, commonly used initial regimens
include corticosteroids in combination with
mycophenolate or azathioprine; whereas, for
patients with inadequate response to these
regimens, adjuvants such as intravenous
immunoglobulin (IVIg) or rituximab are used.
Conclusion: The review findings emphasize the
importance of early diagnosis, early initiation of
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treatment, and use of steroid-sparing adjuvants
to allow a reduced total dose and duration on
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INTRODUCTION
Pemphigus vulgaris (PV) is a chronic,
autoimmune, mucocutaneous, vesiculobullous
disease [1].
The word pemphigus comes from the Greek
word pemphix, which means blister [2]. It is a
rare disease with estimated worldwide annual
incidence of 0.1–0.5 per 100,000 [3]. It occurs in
all racial and ethnic groups with the highest
incidence seen in Ashkenazi Jews [4].
Occurrence is most common during the fifth
and sixth decades of life, although a few cases
have been reported in children [5].
In the majority of cases, PV initially presents
with lesions on the oral mucosa [3]. Often the
first sites affected are those exposed to frictional
trauma including the buccal and lateral tongue
mucosa along the occlusal level, or the gingiva,
but PV can occur on any oral site particularly if
exposed to sharp or acidic foods. The lesions
start as vesicles which rupture easily leaving
erosions and ulcers.
The pathogenesis of pemphigus involves the
presence of circulating and tissue-bound
autoantibodies to the keratinocyte cell surface
desmosomal molecules desmoglein 3 (Dsg3)
and desmoglein 1 (Dsg1). Dsg3 and Dsg1
belong to the cadherin superfamily involved
in cell–cell adhesion. These autoantibodies
cause loss of cell–cell adhesion between
epithelial cells, which results in suprabasilar
intraepithelial vesicle formation [4, 6].
Diagnostic tests include perilesional mucosal
or skin biopsy for histologic examination and
direct immunofluoresence testing. Histologic
findings include presence of intraepithelial
blisters and suprabasilar acantholysis; direct
immunofluorescence findings include IgG
deposits and less commonly IgM and C3
deposits in intercellular spaces in the
epithelium. Blood tests include ELISA testing
for Dsg3 and Dsg1 autoantibodies [7].
Prior to availability of corticosteroid therapy
in the 1950s, PV had a very high fatality rate.
While many treatment options are now
available, corticosteroids in combination with
other drugs still form the mainstay of
treatment. Mortality from pemphigus has
decreased significantly in the last half century
and is now usually due to adverse effects of the
medications used [8, 9].
As a result of the relative rarity of
pemphigus, there are very few randomized
controlled trials. However, numerous
observational studies, case reports, and case
series have been published that report on the
treatment of pemphigus. The objective of this
review was to summarize the findings from all
of the reported human studies including
observational studies and case reports.
METHODS
Publications relating to treatment of PV were
identified by searches of electronic databases
including PubMed, Cochrane, and Google
Scholar through May 2015. Keywords used
included pemphigus vulgaris, autoimmune
vesiculobullous disease, corticosteroids,
azathioprine, rituximab, mycophenolate
mofetil, methotrexate, and IVIg. The full-text
Adv Ther (2016) 33:910–958 911
versions of the papers identified were obtained.
The bibliography of these papers was also
reviewed to identify any additional papers that
did not appear in the electronic search. Only
English-language papers describing treatment
outcomes of patients with PV were included in
this review. A total of 89 papers, which included
21 case reports, 47 case series, 8 RCTs, and 13
observational studies, were included. These
papers were reviewed to obtain information on
publication date, type of study done, age of the
patients, extent of lesion involvement (skin and
mucosa), previous treatments if any,
medications used, duration of use of previous
medications before new ones were started,
duration to first improvement after the start of
medications, follow-up duration, concomitant
medication used along with main drug,
outcome, duration on medication, adverse
effects of drugs, and antibody titer changes
after treatment. This information is summarized
in Tables 1, 2, 3, 4, 5 and 6.
Definitions for some of the terms relating to
treatment outcomes listed in the tables are
described in a consensus statement published
in 2008 [10] as follows:
Complete remission off therapy: Absence of
new and/or established lesions while the patient
is off all systemic therapy for at least 2 months.
Complete remission on therapy: Absence of new
or established lesions while the patient is
receiving minimal therapy.
Minimal therapy: Less than, or equal to,
10 mg/day of prednisone (or the equivalent)
and/or minimal adjuvant therapy for at least 2
months.
Minimal adjuvant therapy: Half of the dose
required to be defined as treatment failure.
Failure of therapy: Failure to control disease
activity (i.e., relapse/flare) with full therapeutic
doses of systemic treatments.
Partial remission off therapy: Presence of
transient new lesions that heal within 1 week
without treatment and while the patient is off
all systemic therapy for at least 2 months.
Partial remission on minimal therapy: Presence
of transient new lesions that heal within 1 week
while the patient is receiving minimal therapy,
including topical steroids [10].
However not all papers included in this
review have described their specific definition
for these terms. If these terms were mentioned
in the publication, we have listed them in the
tables as mentioned in the publication.
This article is based on previously conducted
studies and does not involve any studies of




Since the time of their approval in the 1950s,
corticosteroids have been the mainstay of
treatment of PV.
Mechanism of Action
Corticosteroids have strong anti-inflammatory
and immunosuppressive effects. They affect
almost every aspect of the immune system.
They are potent inhibitors of NFkappa B
activation and have effects on leukocyte
movement, leukocyte function, and humoral
factors. In addition they have inhibitory effects
on many known cytokines [11].
The first case series on corticosteroid use in
PV was published in 1972.
The publications reporting use of
corticosteroids in PV are summarized in
Table 1. This table includes papers that had
systemic corticosteroids as the primary
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medication used. Topical steroids were also used
in many of the reports. In addition, adjuvant
drugs were added in most cases. These
adjuvants included azathioprine,
methotrexate, cyclophosphamide, dapsone,
gold, levamisole, cyclosporine, and
mycophenolate. Adjuvants were usually
administered one at a time; however, they
were changed when lack of response was
noted, and therefore some patients had
multiple adjuvants used sequentially over the
period of treatment.
Publication Type, Patient Profiles, and Sample
Sizes
Seventeen case series were found, with the
number of cases included in the individual
papers ranging from 4 to 1111 cases (a total of
1704 patients were included in the 17 case
series, of which 1681 had PV and 23 had either
pemphigus foliaceous, pemphigus vegetans, or
pemphigus erythematous). Six case reports
describing single patients, one prospective
cohort study (n = 74), two randomized
controlled trials (n = 20 and n = 120), and five
retrospective cohort studies (n = 15, n = 16,
n = 23, n = 32, and n = 154) are summarized
in the Table 1. In all, the total number of cases
in these 31 publications was 2164 out of which
2141 were PV patients, and the rest had
pemphigus foliaceous or pemphigus vegetans
or pemphigus erythematous. These 31 reports
originated from the USA, Israel, Iran, Sri Lanka,
India, Scotland, Italy, Greece, Spain, the
Netherlands, Germany, France, Singapore and
Turkey.
Age at initial diagnosis of PV in these
publications ranged from 4 to 89 years.
Medication Use
Prednisone and prednisolone were the most
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ranged from 15 to 180 mg prednisone
equivalent daily in all but one of the reports
where doses as high as 400 mg daily were used
[12, 13].
Duration of PV Before Corticosteroids Were
Started
This ranged from 0.15 months to 6 years.
Duration of Total Follow-up
Duration of total clinical follow-up of the
individual patients ranged from 9 months to
22 years.
Duration Before Any Clinical Improvement
Was Noted
Seven publications reported on the duration
before any clinical improvement after the start
of corticosteroids was apparent, and this ranged
from 3 days to 19 weeks [14–20].
Duration to Start of Taper of Corticosteroids
Information regarding tapering of
corticosteroids was reported in seven
publications. The duration before the start of
taper of corticosteroids ranged from 0.5 to
12 months in these seven publications
comprising of 156 patients.
Duration to Complete Remission (On and Off
Therapy)
Duration to complete remission on therapy was
reported in 15 articles, and ranged from 1.5 to
42 months (3.5 years), in 797 patients.
Duration to complete remission off therapy
was reported in 15 articles, and ranged from 4 to
120 months (10 years) in 321 patients.
Remission
Of a total of 2141 patients reported on in
Table 1, at the end of follow-up 97 patients
had achieved partial remission on therapy, 797
patients had achieved complete remission on
therapy, and 321 patients had achieved
complete remission off therapy. A total of 485
patients were still being treated at the time of
publication, 156 patients were lost to follow-up,
death occurred in 177 patients, and 47 patients
were classified as non-responders and referred
elsewhere for treatment.
Duration of Medication Use
Total duration of medication use for all reported
patients including those still on therapy at the
time of publication ranged from 1.5 to
240 months (20 years).
Follow-up Duration After Discontinuation
of Medications
Follow-up ranged from2to156 months (13 years)
after discontinuation of treatment in the 321
patients with complete remission off therapy,
during which time there was no recurrence.
Mortality
Death occurred in a total of 177 of 2141 patients
(8.26 %) with PV in all reports. These included
deaths from all causes. Of these, the reports
published between 1970 and 1980 included 127
patients with 61 deaths (48.03 %), between
1981 and 1990 included 183 patients with 26
deaths (14.2 %), between 1991 and 2000
included 190 patients with 7 deaths (3.6 %),
and those published between 2001 and 2010
included 1589 patients with 83 deaths (5.2 %).
Adverse Effects
Adverse effects from corticosteroids reported in
these papers included Cushingoid symptoms,
diabetes mellitus, osteoporosis, hypertension,
insomnia, GI upset, increased weight,
candidiasis, tuberculosis, mood change,
abnormal liver function test, fungal and viral
infection, fatigue, acute psychosis,
Adv Ther (2016) 33:910–958 923
hyperglycemia, electrolyte imbalance,
hypocalcemia, acidosis, hyperkalemia,
phlebitis, herpes simplex, hyperlipidemia,
bone marrow depression, cataract, and
myopathy.
Azathioprine (AZA)
Azathioprine was approved by the US Food and
Drug Administration (FDA) in 1968 as an
immunosuppressant to prevent organ
transplant rejection.
Mechanism of Action
This drug restricts synthesis of DNA, RNA, and
proteins by inhibiting metabolism of purine. It
also interferes with cellular metabolism and
mitosis [8].
Publication Type, Patient Profiles, and Sample
Sizes
The studies reporting use of AZA in PV are
summarized in Tables 1 and 2. Of the 31 papers
in Table 1, 17 had included azathioprine as one
of the treatment modalities. Table 2 includes
only those publications that reported on
comparative analyses of outcomes for patients
on prednisone alone vs. those on prednisone in
combination with azathioprine. The first case
series on use of AZA in PV was published in
1986.
One randomized double blind controlled
study (n = 56) and two retrospective cohort
studies (n = 48 and n = 36) are summarized in
Table 2. In all, a total of 140 patients were
included in these three reports.
Age at initial diagnosis of PV in these
publications ranged from 16 to 83 years.
Medication Use
The dosage of azathioprine used was 40 mg/day
up to 3 mg/kg/day in all reports. Prednisone was
used concomitantly with azathioprine in all
reports. Azathioprine was added at the onset of
treatment in the three reports in Table 2 and
sometime after onset of corticosteroid use in the
reports in Table 1.
Duration of PV Before Azathioprine Was
Started in the Reports Summarized in Table 2
This ranged from 4 to 10 months.
Duration of Follow-up in the Reports
Summarized in Table 2
Duration of clinical follow-up of the individual
patients on azathioprine in these reports ranged
from 12 months to 10 years.
Duration to Complete Remission (On and Off
therapy) for the Azathioprine Plus Prednisone
Group in Table 2
Duration to complete remission on therapy was
reported in three articles and, ranged from 6 to
12 months, in 67 patients.
Duration to complete remission off therapy
was reported in two articles and, ranged from 6
to 12 months, in eight patients.
Patients on prednisone and azathioprine had
better responses as compared to patients on
prednisone alone, with more patients achieving
remission, and with fewer side effects.
Remission
Of a total of 140 patients, at the end of
follow-up 11 patients had achieved partial
remission and mean duration to achieve that
was 234.4 days, 67 patients had achieved
complete remission on therapy, and eight
patients had achieved complete remission off
therapy. Six patients were still being treated at
the time of publication. No response was seen
in 17 patients. Treatment failed in five patients.
Death occurred in 13 patients and 13 patients
were lost to follow-up.
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Adverse Effects Reported in Table 2
Adverse effects in patients on azathioprine and




problems, lethargy, weight gain, muscle
weakness, adrenal suppression, alopecia, and
rash-like skin disorders.
Mycophenolate Mofetil (MMF)
Mycophenolate Mofetil was approved by the
FDA in 1995 as an immunosuppressant to
prevent organ transplant rejection.
Mechanism of Action
After oral administration, mycophenolate is
absorbed rapidly and then gets converted to
the active metabolite mycophenolic acid (MPA).
This active metabolite inhibits inosine
monophosphate dehydrogenase selectively and
hence inhibits de novo pathway of purine
synthesis in T and B cells, which results in
inhibition of T and B cell proliferation [20].
Publications reporting use of MMF as an
adjuvant to corticosteroids in PV were included
in Table 1. Additional papers which have reported
on the use of mycophenolate in patients with
refractory PV (previous treatment with
corticosteroids and azathioprine was unsuccessful
in achieving remission) are summarized inTable 3.
Of31papers inTable 1, threehad includedMMFas
one of the treatment modalities.
Publication Type, Patient Profiles, and Sample
Sizes
The first case series on use of MMF in PV
patients was published in 1999.
Four case series were included, with the
number of cases included in the individual
papers ranging from 9 to 31 cases (a total of 64
patients in four case series); two were case
reports describing single patients and two were
randomized prospective trials (n = 94 and
n = 21, respectively). One additional
randomized clinical trial enrolled both PV and
PF patients [n = 36 (PV) ? 11 (PF); results were
not reported separately for the PV and PF
patients in this study] and one retrospective
analysis (n = 18) is summarized in the tables.
The total number of patients treated with MMF
in these 10 reports was 247.
Age at initial diagnosis of PV in these
publications ranged from 6 to 78 years.
Medication Use and Duration of PV Before
MMF Was Started
Medication use and duration of PV before MMF
was started ranged from 1month to 14 years.
During this period patients were on a
combination of corticosteroids and azathioprine.
At the time mycophenolate was added, the
azathioprine was discontinued; however, the
patients continued to be on corticosteroids. One
publication (Powell et al.) reported on patients in
whom multiple medications like methotrexate,
cyclophosphamide, IVIg, dapsone, gold,
thalidomide, and minocycline along with
azathioprine and corticosteroids were tried prior
to addition of mycophenolate [21].
The starting dosage of mycophenolate
mofetil used was 2–3 g/day in all reports.
Duration of Follow-up
Duration of clinical follow-up of the individual
patients after the start of MMF therapy ranged
from 5 to 130 months.
Duration Before Any Clinical Improvement
Was Noted
First improvement in lesions was noted after
2–24 weeks after addition of mycophenolate to
the existing medication regimen.
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Duration to Complete Remission (On and Off
Therapy) After Addition of MMF
Duration to complete remission on therapy was
reported in six articles and, ranged from 2 to
16 months, in 104 patients.
Duration to complete remission off therapy
was reported in one article and, ranged from 24
to 36 months, in 17 patients.
Remission
Of a total of 247 patients, 104 patients achieved
complete remission on therapy and 17 patients
achieved complete remission off therapy. A total
of 76 patients achieved partial remission, and the
duration to achieve that ranged from 129 to
150 days after the start of therapy. FailureofMMF
was mentioned in four reports (N = 176) in 18
patients who were referred for treatment with
rituximab or IVIg. Two patients were still being
treated at the time of publication, 29 patients
were lost to follow-up or withdrawn from study,
and death occurred in one patient.
Adverse Effects
Adverse effects inpatients onmycophenolate and
corticosteroids reported in these publications
included gastrointestinal problems, myalgia,
neutropenia, and lymphopenia, which were the
most common side effects reported. Headache,
increased fasting blood glucose level, and
hypertension, nausea, depression, pyrexia,
redistribution of body fat, eye disease, weight
gain, fatigue, and arthralgia were also reported.
In the one publication where enteric coated
mycophenolate sodium was used, the side
effects reported were headache and increased
fasting blood glucose level.
Intravenous Immunoglobulin (IVIg)
IVIg was approved by the FDA for primary
immune deficiency in 1952 [22].
Mechanism of Action
Intravenous immunoglobulins (IVIg) are
obtained from a plasma pool of thousands of
donors [22].
These immunoglobulins neutralize and slow
down the production of circulating pemphigus
antibodies [23].
Publication Type, Patient Profiles, and Sample
Sizes
The studies reporting use of IVIg in PV are
summarized in Table 4. The first case series on
IVIg in PV was published in 2002.
One case series (n = 6), two case reports
describing single patients, and one
randomized placebo-controlled double-blind
trial (n = 40) are summarized in Table 4, with a
total of 48 patients included in these four
papers. These reports included patients
previously treated with corticosteroids,
cyclophosphamide, azathioprine, and
methotrexate without adequate response, prior
to start of IVIg.
Age at initial diagnosis of PV in these
publications ranged from 41 to 78 years.
Medication Use
The dosage of IVIg used was 400 mg/kg/day for
5 days followed by long- or short-term single
doses of 400 mg/kg/day every 6 weeks for
6 months to 1 year. Concomitant drugs mainly
used were corticosteroids in the published
studies.
Duration of PV Before IVIg Was Started
This ranged from 2 months to 5 years.
Duration of Total Follow-up
Duration of total clinical follow-up of the
individual patients ranged from 2 months to
2 years.
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Duration Before Any Clinical Improvement
Was Noted
First improvement in lesionswas reportedwithin
2–3 weeks of first IVIg infusion in all 48 patients.
Duration to Start of Taper of Corticosteroids
Only one case series of six patients described the
duration to the start of taper of corticosteroids
and only mentioned that the median time was
16 days after the start of IVIg infusions.
Duration to Complete Remission (On and Off
Therapy)
This information was not available from the
publications. However, all reports discussed
improvement in all patients treated with IVIg; in
sixpatients thiswasachievedwithin3 weeksand in
29 patients within 3–12months. Thirteen patients
in the placebo group had no improvement.
Adverse Effects in Patients on IVIg Reported
in Table 4
Headache, abdominal discomfort, nausea,
constipation, lymphopenia, hepatitis C, and
palpitations.
Methotrexate
Methotrexate was approved by the FDA for
psoriasis in 1971 and for rheumatoid arthritis in
1988.
Mechanism of Action
Methotrexate inhibits the metabolism of folic
acid and is used as a chemotherapeutic and
immunosuppressive agent. Methotrexate
allosterically inhibits dihydrofolate reductase,
which plays a role in tetrahydrofolate synthesis.
As folic acid is essential for normal cell growth
and replication, methotrexate is effective
against malignant cell growth and has
anti-inflammatory effects [24].
Publication Type, Patient Profiles, and Sample
Sizes
The studies reporting use of methotrexate in PV
are summarized in Table 5. The first case series
on MTX in PV was published in 1969.
Publications reporting use of methotrexate
in PV were included in Table 1 (7 of 31 papers
included methotrexate), and additional papers
that reported on the use of methotrexate as the
initial adjunctive treatment to corticosteroids
are summarized in Table 5.
Six case series were included, with the
number of cases included in the individual
papers ranging from 3 to 53 cases (total of 121
patients in six case series), and one retrospective
cohort study (n = 30) are summarized in the
tables. In all, a total of 151 patients treated with
MTX are reported in seven studies.
Age at initial diagnosis of PV in these
publications ranged from 20 to 83 years.
Medication Use
The dosage of MTX used in these publications
ranged from 12.5 to 150 mg/week. Concomitant
drug used along with methotrexate was
prednisone.
Duration of PV Before Methotrexate Was
Started
This ranged from 11 months to 7 years.
Duration of Follow-up
Duration of clinical follow-up of the individual
patients after the start of MTX ranged from 5 to
15 years.
Duration Before Any Clinical Improvement
Was Noted
First improvement in lesions was reported
within 1–30 weeks after the start of
methotrexate therapy.
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Duration to Complete Remission (On and Off
Therapy)
Duration to complete remission on therapy was
reported in six articles and, ranged from 1 to
30 weeks, in 51 patients.
Duration to complete remission off therapy
was reported in one article and, ranged from
3 months to 8 years, in 14 patients.
Remission
Of a total of 151 patients, at the end of
follow-up, 56 patients had achieved partial
remission and the duration to achieve that
was within 6 months after the start of MTX
therapy; 51 patients had achieved complete
remission on therapy; and 14 patients had
achieved complete remission off therapy.
Twelve patients were lost to follow-up.
Treatment was not effective in nine patients.
Death unrelated to MTX occurred in six
patients.
Adverse Effects in Patients on MTX Reported
in Table 5
Nausea, leukopenia, GI upset, fatigue, bacterial
infection, bronchopneumonia, septicemia,
necrotizing gingivitis, diarrhea, and pyoderma.
Rituximab
Rituximab was approved in 1997 by the FDA to
treat B cell non-Hodgkin lymphoma and in
2006 to treat rheumatoid arthritis.
Mechanism of Action
Rituximab is a human–mouse chimeric
monoclonal antibody to CD20 antigen on B
cells. CD20 is a membrane protein that is
involved in activation and proliferation of B
cell [25].
Publication Type, Patient Profiles, and Sample
Sizes
The studies reporting use of rituximab in PV are
summarized in Table 6. The first case series on
PV treated by rituximab was published in 2002.
Publications which have reported on the use
of rituximab in patients with refractory PV
(previous treatment with corticosteroids,
azathioprine, methotrexate, mycophenolate,
IVIg, and cyclophosphamide were unsuccessful
in achieving remission) are summarized in
Table 6.
Nineteen case series were included, with
the number of cases included in the
individual papers ranging from 3 to 84 cases
(total of 339 patients in 19 case series), 24
were case reports describing single patients,
three open label pilot studies (n = 5, n = 9,
and n = 17), one randomized prospective trial
(n = 15), two retrospective analysis (n = 25
and n = 19), and one phase 2 clinical trial
(n = 40) are summarized in the tables. In all, a
total of 493 patients were treated with
rituximab.
Age of patients treated with rituximab for PV
in these publications ranged from 15 to 86.
Medication Use
The dosage of rituximab used was 375 mg/m2
body surface area (BSA) once weekly for 4 weeks
or two infusions of 1000 mg at 2 weeks apart.
Previously failed treatments before rituximab
were prednisone, MMF, AZA, IVIg, MTX,
dapsone, CyclP, plasmapheresis, protein A
immunoadsorption, cyclosporine,
dexamethasone, and gold. Concomitant drug
used was prednisone, MMF, AZA, and IVIg.
Duration of PV Before Rituximab Was Started
This ranged from 1 months to 23 years.
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Duration of Follow-up
Duration of clinical follow-up of the individual
patients after the start of rituximab therapy
ranged from 6 to 80 months.
Duration Before Any Clinical Improvement
Was Noted
First improvement in lesions was reported
within 2 weeks to 8 months after the first
rituximab infusion.
Duration to Complete Remission (On and Off
Therapy)
Duration to complete remission on therapy was
reported in 32 articles and, ranged from 1 to
36 months, in 184 patients.
Duration to complete remission off therapy
was reported in 22 articles and, ranged from 2 to
59 months, in 229 patients.
Remission
Of a total of 493 patients reported in Table 6, at
the end of follow-up, 80 patients had achieved
partial remission, and duration to achieve that
ranged from 3 to 27 months; 184 patients
achieved complete remission on therapy; and
229 patients achieved complete remission off
therapy. Death due to sepsis occurred in three
patients. Relapses were seen in nine patients. No
response to rituximab was seen in 11 patients.
However, these patients had response after
addition of IVIg or additional cycles of
rituximab.
Adverse Effects in Patients on Rituximab
Reported in Table 6
Local pain, nausea, cough, chills, sepsis, and
angioedema related to infusion.
OTHER MEDICATIONS
Other Less Commonly Used Adjuvants
from Studies Listed in Table 1
Gold salts These are widely used in treatment of
rheumatoid arthritis. Their action is related to
their T cell-mediated immunosuppressive
properties [23].
Plasmapheresis This is used for removing
antibodies from the circulation. Reduction in
antibodies triggers production of new antibodies
as a result of a feedback mechanism [23].
Immunoadsorption With plasmapheresis
protective immunoglobulins, albumin, and
clotting factors are removed along with
harmful pemphigus antibodies.
Immunoadsorption selectively traps the
harmful pemphigus antibodies through the
sulfhydryl filtering membrane. Thus,
protective antibodies and plasma components
are returned [23].
Cyclophosphamide It has been widely used in
the treatment of cancer and also as an
immunosuppressant. This drug is converted in
the liver to its active metabolites
aldophosphamide and phosphoramide
mustard. These bind to DNA and inhibit its
replication, which leads to cell death. It can be
given orally as well as intravenously. One report
described cyclophosphamide use in seven
patients for treating PV in combination with
corticosteroids and azathioprine [26].
Nicotinamide and tetracycline These were used
as steroid-sparing agent in combination with
corticosteroids and azathioprine in one study of
six patients with PV. Their mechanism of action
is unclear [27].
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DISCUSSION
In this paper, we have summarized the
published literature on the management of
PV. The published papers were mostly case
reports, case series, observational studies, and
only eight randomized controlled trials.
As a result of the relative rarity of
pemphigus, published randomized trials are
limited, which makes it difficult to evaluate
the efficacy of different treatment regimens in
this disease. This also precludes conduct of a
meta-analysis. A Cochrane review published in
2009 concluded that ‘‘there is inadequate
information available at present to ascertain
the optimal therapy for pemphigus vulgaris’’
[28]. While this remains the case, a summary of
the literature provides information on disease
course and prognosis as well as medication
options, treatment responses, and side effects,
which are of relevance to clinicians who treat
this disease and patients who suffer from it.
The treatment options for PV have increased
over the years. The early publications from the
1970s reported use of high corticosteroid doses
over prolonged intervals and significant
associated side effects. Later reports on PV
management described use of corticosteroids
along with steroid-sparing adjuvants, which
allows a reduction in the total dose of
corticosteroids used over the course of the
treatment with a reduction in observed
morbidity. The more commonly used
steroid-sparing medications in the published
reports include azathioprine, methotrexate, and
mycophenolate mofetil. More recently, IVIg
and rituximab have been used, mainly in
patients with recalcitrant PV.
Overall, the mortality and morbidity from
PV and the medications used in its treatment
are considerably lower in the more recent
publications than in the early reports.
The reported treatment response in patients
with PV has varied significantly. Prognostic
factors that have been identified include initial
severity and extent of disease, with higher
severity being predictive of poorer prognosis.
[29]. Perhaps related to this is the fact that early
initiation of treatment before the disease
becomes too severe or widespread has been
associated with improved prognosis [30, 31].
Once treatment is initiated, good initial
response to treatment has also been found to
be indicative of a better prognosis [32].
Most reports described medication courses of
long duration before remission off therapy was
achieved (between 5 and 10 years in the
majority of patients with the range across all
studies being 3 months to 27 years). However,
Herbst and Bystryn described a group of 40
patients in whom 10 (25 %) patients achieved
complete and long-lasting remission within
2 years of treatment; a subgroup of patients
with PV, with a mild course of the disease
requiring short courses of systemic medications
or topical medication alone to induce remission
[5, 32, 33]; and at the other extreme a subgroup
that is resistant to treatment and required high
doses and prolonged therapy have also been
described [29, 32, 35].
The role of baseline laboratory tests, such as
quantification of antibodies as predictors of
disease course, has not been established. A
recent study reported that a higher level of
anti-Dsg1 autoantibodies (C100 U/mL) at
diagnosis was associated with poorer prognosis
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in univariate analyses; however, this did not
remain significant after adjustment for age [36].
Periodic antibody titers measured by indirect
immunofluorescence or ELISA testing have not
consistently shown correlation with clinical
activity of PV [37]. Most authors in the listed
papers reported using clinical response alone to
guide medication taper.
Reports using rituximab described remission
off therapy in a shorter time frame (ranging
from 2 months to 5 years) as compared to other
medication combinations; this observation
suggested that while the initial side effects
may be significant, a shorter total duration of
therapy may be possible with use of rituximab.
Because rituximab is a more recent drug, first
introduced in 1997, long-term side effects are
not well characterized at this time.
CONCLUSION
The findings from this review emphasize the
importance of early diagnosis of PV, early
initiation of treatment, and use of a treatment
regimen which includes a steroid-sparing
adjuvant to allow a reduced total dose and
duration on corticosteroids. For the majority of
patients in these reports, a long-term course on
medications lasting about 5–10 years was
observed; however, subgroups of patients
requiring shorter courses or those needing
longer-term therapy were also described. In
recent publications, commonly used initial
regimens include corticosteroids in
combination with mycophenolate or
azathioprine; whereas, for patients with
inadequate response to these regimens,
adjuvants such as IVIG or rituximab were used
[21, 38, 39]. This review also highlights the need
for more controlled trials to determine optimal
treatment regimens for patients with PV.
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